PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Application of Serum ELAVL4 (HuD) Antigen Assay for Small Cell Lung Cancer Diagnosis.

Abstract The ELAVL4 (HuD) is a neuron-specific RNA-binding protein expressed in 100% of small cell lung cancer (SCLC) cells and over 50% of neuroblastoma cells. The aim of this study was to investigate the serum HuD concentration in SCLC patients and the possibility of its utilization as a biomarker of small cell lung cancer.
PMID
Related Publications

Clinical value of combined detection of serum tumor markers in lung cancer diagnosis.

Application of serum NY-ESO-1 antibody assay for early SCLC diagnosis.

A Highly Efficient Gene Expression Programming (GEP) Model for Auxiliary Diagnosis of Small Cell Lung Cancer.

Molecular detection of neuron-specific ELAV-like-positive cells in the peripheral blood of patients with small-cell lung cancer.

Prediction of lung cancer based on serum biomarkers by gene expression programming methods.

Authors

Mayor MeshTerms

Biomarkers, Tumor

Keywords

ELISA

HuD

SCLC

early diagnosis

lung cancer

Journal Title anticancer research
Publication Year Start




PMID- 28739747
OWN - NLM
STAT- MEDLINE
DA  - 20170725
DCOM- 20170803
LR  - 20170803
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 8
DP  - 2017 Aug
TI  - Application of Serum ELAVL4 (HuD) Antigen Assay for Small Cell Lung Cancer
      Diagnosis.
PG  - 4515-4522
AB  - BACKGROUND/AIM: The ELAVL4 (HuD) is a neuron-specific RNA-binding protein
      expressed in 100% of small cell lung cancer (SCLC) cells and over 50% of
      neuroblastoma cells. The aim of this study was to investigate the serum HuD
      concentration in SCLC patients and the possibility of its utilization as a
      biomarker of small cell lung cancer. MATERIALS AND METHODS: Our study included 47
      SCLC cases and 29 normal controls. Indirect competitive inhibition ELISA method
      was established to detect HuD antigen of serum samples. To design the ELISA
      system, purified antigen and real positive and negative serum samples were used, 
      and checkerboard titration was performed. The value of current serum biomarkers
      (Pro-GRP, NSE, CYFRA21-1 and CEA) was obtained from a clinical laboratory.
      RESULTS: The HuD antigen concentration in the SCLCgroup was significantly higher 
      than that in the normal group (p<0.01). The cut-off value, specificity and
      sensitivity were 60 ng/ml, 89.7% and 74.5%, respectively. The best linear range
      was 9.75~600 ng/ml. The sensitivity of the HuD-ELISA assay was much better than
      the current biomarkers-CEA, NSE and pro-GRP. Also,it was equal to or better than 
      the combined use of two or three indicators. CONCLUSION: The high titres of HuD
      in SCLC patients and preferable consistency suggested that HuD may serve as a
      potential diagnostic criterium for SCLC and may serve as a marker of disease
      progression.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Wang, Feifei
AU  - Wang F
AD  - School of Basic Medical Sciences, Capital Medical University, Beijing Key
      Laboratory of Cancer Invasion & Metastasis Research, Beijing, P.R. China.
FAU - Lu, Jianyi
AU  - Lu J
AD  - School of Basic Medical Sciences, Capital Medical University, Beijing Key
      Laboratory of Cancer Invasion & Metastasis Research, Beijing, P.R. China.
FAU - Li, Shentao
AU  - Li S
AD  - School of Basic Medical Sciences, Capital Medical University, Beijing Key
      Laboratory of Cancer Invasion & Metastasis Research, Beijing, P.R. China.
FAU - Huo, Xueyun
AU  - Huo X
AD  - School of Basic Medical Sciences, Capital Medical University, Beijing Key
      Laboratory of Cancer Invasion & Metastasis Research, Beijing, P.R. China.
FAU - Liu, Xin
AU  - Liu X
AD  - School of Basic Medical Sciences, Capital Medical University, Beijing Key
      Laboratory of Cancer Invasion & Metastasis Research, Beijing, P.R. China.
FAU - DU, Xiaoyan
AU  - DU X
AD  - School of Basic Medical Sciences, Capital Medical University, Beijing Key
      Laboratory of Cancer Invasion & Metastasis Research, Beijing, P.R. China.
FAU - Li, Changlong
AU  - Li C
AD  - School of Basic Medical Sciences, Capital Medical University, Beijing Key
      Laboratory of Cancer Invasion & Metastasis Research, Beijing, P.R. China.
FAU - Wang, Jinghui
AU  - Wang J
AD  - Department of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Research 
      Institute, Beijing Chest Hospital, Capital Medical University, Beijing, P.R.
      China [email protected] [email protected]
FAU - Chen, Zhenwen
AU  - Chen Z
AD  - School of Basic Medical Sciences, Capital Medical University, Beijing Key
      Laboratory of Cancer Invasion & Metastasis Research, Beijing, P.R. China
      [email protected] [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (ELAV-Like Protein 4)
SB  - IM
MH  - Aged
MH  - *Biomarkers, Tumor
MH  - Cloning, Molecular
MH  - ELAV-Like Protein 4/*blood
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Gene Expression
MH  - Humans
MH  - Lung Neoplasms/*blood/*diagnosis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Sensitivity and Specificity
MH  - Small Cell Lung Carcinoma/*blood/*diagnosis
OTO - NOTNLM
OT  - ELISA
OT  - HuD
OT  - SCLC
OT  - early diagnosis
OT  - lung cancer
EDAT- 2017/07/26 06:00
MHDA- 2017/08/05 06:00
CRDT- 2017/07/26 06:00
PHST- 2017/06/08 [received]
PHST- 2017/07/03 [revised]
PHST- 2017/07/04 [accepted]
AID - 37/8/4515 [pii]
PST - ppublish
SO  - Anticancer Res. 2017 Aug;37(8):4515-4522.